Fetal bovine serum (FBS) is the most commonly used supplement for ex vivo expansion of human mesenchymal stem cells (hMSCs) for bone tissue engineering applications. However, from a clinical standpoint, it is important to substitute animal-derived products according to current good manufacturing practice (cGMP) guidelines. Humanized alternatives to FBS include three categories of products: human serum (HS), human platelet derivatives (HPDs)—including platelet lysate (PL) or platelet releasate (PR), produced by freeze/thawing or chemical activation of platelet concentrates, respectively, and chemically defined media (serum-free) (CDM). In this systematic literature review, the in vitro and in vivo osteogenic potential of hMSCs expanded in humanized (HS-, HPD-, or CDM-supplemented) media versus hMSCs expanded in FBS-supplemented media, was compared. In addition, PL and PR were compared in terms of their growth factor (GF)/cytokine-content and cell-culture efficacy. When using either 10–20% autologous or pooled HS, 3–10% pooled HPDs or CDM supplemented with GFs, in comparison with 10–20% FBS, a majority of studies reported similar or superior in vitro proliferation and osteogenic differentiation, and in vivo bone formation in ectopic or orthotopic rodent models. Moreover, a trend for higher GF content was observed in PL versus PR, although evidence for cell culture efficacy is limited. In summary, humanized supplements seem at least equally effective as FBS for hMSC expansion and osteogenic differentiation. Although pooled HPDs appear to be the most favorable supplement for large-scale hMSC expansion, further efforts are needed to standardize the preparation and composition of these products in compliance with cGMP standards.
Get full access to this article
View all access options for this article.
References
1.
GötzC., WarnkeP.H., and KolkA.Current and future options of regeneration methods and reconstructive surgery of the facial skeleton. Oral Surg Oral Med Oral Pathol Oral Radiol, 120, 315, 2015.
2.
FretwurstT., GadL.M., NelsonK., and SchmelzeisenR.Dentoalveolar reconstruction. Curr Opin Otolaryngol Head Neck Surg, 23, 316, 2015.
3.
NkenkeE., and NeukamF.W.Autogenous bone harvesting and grafting in advanced jaw resorption: morbidity, resorption and implant survival. Eur J Oral Implantol, 7Suppl 2, S203, 2014.
4.
Al-NawasB., and SchiegnitzE.Augmentation procedures using bone substitute materials or autogenous bone—a systematic review and meta-analysis. Eur J Oral Implantol, 7, 219, 2014.
5.
MilinkovicI., and CordaroL.Are there specific indications for the different alveolar bone augmentation procedures for implant placement? A systematic review. Int J Oral Maxillofac Surg, 43, 606, 2014.
6.
ShanbhagS., and ShanbhagV.Clinical applications of cell-based approaches in alveolar bone augmentation: a systematic review. Clin Implant Dent Relat Res, 17, e17, 2015.
7.
HanleyP.J., MeiZ., da Graca Cabreira-HansenM., KlisM., LiW., ZhaoY., DurettA.G., ZhengX., WangY., GeeA.P., and HorwitzE.M.Manufacturing mesenchymal stromal cells for phase I clinical trials. Cytotherapy, 15, 416, 2013.
8.
LohanP., ColemanC.M., MurphyJ.M., GriffinM.D., RitterT., and RyanA.E.Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned? Stem Cell Res Ther, 5, 99, 2014.
9.
OppenheimerA.J., MesaJ., and BuchmanS.R.Current and emerging basic science concepts in bone biology: implications in craniofacial surgery. J Craniofac Surg, 23, 30, 2012.
10.
ShanbhagS., PandisN., MustafaK., NyengaardJ., and StavropoulosA.Alveolar bone tissue engineering in critical-size defects of experimental animal models: a systematic review and meta-analysis. J Tissue Eng Regen Med, 2016, doi: 10.1002/term.2198.
11.
Padial-MolinaM., ValleF., LanisA., MesaF., Dohan EhrenfestD.M., WangH.-L., and Galindo-MorenoP.Clinical application of mesenchymal stem cells and novel supportive therapies for oral bone regeneration. Biomed Res Int, 2015, 16, 2015.
12.
BiebackK., SchallmoserK., KlüterH., and StrunkD.Clinical protocols for the isolation and expansion of mesenchymal stromal cells. Transfus Med Hemother, 35, 286, 2008.
13.
SpeesJ.L., GregoryC.A., SinghH., TuckerH.A., PeisterA., LynchP.J., HsuS.C., SmithJ., and ProckopD.J.Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther, 9, 747, 2004.
14.
BiebackK.Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transfus Med Hemother, 40, 326, 2013.
15.
RusselW.M.S., and BurchR.L.The Principles of Humane Experimental Technique. London: Methuen & Co., 1959. [Special edition published by Universities Federation for Animal Welfare (UFAW), 1992].
16.
MendicinoM., BaileyA.M., WonnacottK., PuriR.K., and BauerS.R.MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell, 14, 141, 2014.
17.
HemedaH., GiebelB., and WagnerW.Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. Cytotherapy, 16, 170, 2014.
18.
IkebeC., and SuzukiK.Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. Biomed Res Int, 2014, 951512, 2014.
19.
TekkatteC., GunasinghG.P., CherianK.M., and SankaranarayananK.“Humanized” stem cell culture techniques: the animal serum controversy. Stem Cells Int, 2011, 504723, 2011.
20.
ShihD.T.B., and BurnoufT.Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion. N Biotechnol, 32, 199, 2015.
21.
BurnoufT., StrunkD., KohM.B., and SchallmoserK.Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials, 76, 371, 2016.
22.
FossB., BruserudO., and HervigT.Platelet-released supernatants enhance hematopoietic stem cell proliferation in vitro. Platelets, 19, 155, 2008.
23.
Rubio-AzpeitiaE., and AndiaI.Partnership between platelet-rich plasma and mesenchymal stem cells: in vitro experience. Muscles Ligaments Tendons J, 4, 52, 2014.
24.
AstoriG., AmatiE., BambiF., BernardiM., ChieregatoK., SchaferR., SellaS., and RodeghieroF.Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future. Stem Cell Res Ther, 7, 93, 2016.
25.
MannelloF., and TontiG.A.Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula?. All that glitters is not gold! Stem Cells, 25, 1603, 2007.
26.
PellegriniG., SeolY.J., GruberR., and GiannobileW.V.Pre-clinical models for oral and periodontal reconstructive therapies. J Dent Res, 88, 1065, 2009.
27.
HalmeD.G., and KesslerD.A.FDA regulation of stem-cell-based therapies. N Engl J Med, 355, 1730, 2006.
28.
MuschlerG.F., RautV.P., PattersonT.E., WenkeJ.C., and HollingerJ.O.The design and use of animal models for translational research in bone tissue engineering and regenerative medicine. Tissue Eng Part B Rev, 16, 123, 2010.
29.
ScottM.A., LeviB., AskarinamA., NguyenA., RackohnT., TingK., SooC., and JamesA.W.Brief review of models of ectopic bone formation. Stem Cells Dev, 21, 655, 2012.
30.
MoherD., LiberatiA., TetzlaffJ., and AltmanD.G.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, e1000097, 2009.
31.
HooijmansC.R., RoversM.M., de VriesR.B.M., LeenaarsM., Ritskes-HoitingaM., and LangendamM.W.SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol, 14, 43, 2014.
32.
YanX.-Z., YangF., JansenJ.A., de VriesR.B.M., and van den BeuckenJ.J.J.P.Cell-based approaches in periodontal regeneration: a systematic review and meta-analysis of periodontal defect models in animal experimental work. Tissue Eng Part B Rev, 21, 411, 2015.
33.
KuznetsovS.A., MankaniM.H., and RobeyP.G.Effect of serum on human bone marrow stromal cells: ex vivo expansion and in vivo bone formation. Transplantation, 70, 1780, 2000.
34.
MatsuoA., YamazakiY., TakaseC., AoyagiK., and UchinumaE.Osteogenic potential of cryopreserved human bone marrow-derived mesenchymal stem cells cultured with autologous serum. J Craniofac Surg, 19, 693, 2008.
35.
PytlikR., StehlikD., SoukupT., KalbacovaM., RypacekF., TrcT., MulinkovaK., MichnovaP., KideryovaL., ZivnyJ., KlenerP.Jr., VeselaR., TrnenyM., and KlenerP.The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering. Biomaterials, 30, 3415, 2009.
36.
StehlikD., PytlikR., RychtrmocovaH., VeselaR., KopecnyZ., and TrcT.[Xenogeneic protein free cultivation of mesenchymal multipotent stromal cells]. Acta Chir Orthop Traumatol Cech, 78, 537, 2011.
37.
TakedaA., YamazakiY., BabaK., IshiguroM., AoyagiK., IkemotoS., and UchinumaE.Osteogenic potential of human bone marrow-derived mesenchymal stromal cells cultured in autologous serum: a preliminary study. J Oral Maxillofac Surg, 70, e469, 2012.
38.
PisciottaA., RiccioM., CarnevaleG., BerettiF., GibelliniL., MaraldiT., CavalliniG.M., FerrariA., BruzzesiG., and De PolA.Human serum promotes osteogenic differentiation of human dental pulp stem cells in vitro and in vivo. PLoS One, 7, e50542, 2012.
39.
RobertsS.J., OwenH.C., TamW.L., SolieL., Van CromphautS.J., Van den BergheG., and LuytenF.P.Humanized culture of periosteal progenitors in allogeneic serum enhances osteogenic differentiation and in vivo bone formation. Stem Cells Transl Med, 3, 218, 2014.
40.
VogelJ.P., SzalayK., GeigerF., KramerM., RichterW., and KastenP.Platelet-rich plasma improves expansion of human mesenchymal stem cells and retains differentiation capacity and in vivo bone formation in calcium phosphate ceramics. Platelets, 17, 462, 2006.
41.
PrinsH.J., RozemullerH., Vonk-GriffioenS., VerweijV.G., DhertW.J., Slaper-CortenbachI.C., and MartensA.C.Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute for fetal bovine serum. Tissue Eng Part A, 15, 3741, 2009.
42.
MullerA.M., DavenportM., VerrierS., DroeserR., AliniM., Bocelli-TyndallC., SchaeferD.J., MartinI., and ScherberichA.Platelet lysate as a serum substitute for 2D static and 3D perfusion culture of stromal vascular fraction cells from human adipose tissue. Tissue Eng Part A, 15, 869, 2009.
43.
ChevallierN., AnagnostouF., ZilberS., BodivitG., MaurinS., BarraultA., BierlingP., HernigouP., LayrolleP., and RouardH.Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials, 31, 270, 2010.
44.
TodeschiM.R., El BacklyR., CapelliC., DagaA., PatroneE., IntronaM., CanceddaR., and MastrogiacomoM.Transplanted umbilical cord mesenchymal stem cells modify the in vivo microenvironment enhancing angiogenesis and leading to bone regeneration. Stem Cells Dev, 24, 1570, 2015.
45.
TchangL.A., PippengerB.E., TodorovA.Jr., WolfF., BurgerM.G., JaquieryC., BiebackK., MartinI., SchaeferD.J., and ScherberichA.Pooled thrombin-activated platelet-rich plasma: a substitute for fetal bovine serum in the engineering of osteogenic/vasculogenic grafts. J Tissue Eng Regen Med, 11, 1542, 2015.
46.
AgataH., WatanabeN., IshiiY., KuboN., OhshimaS., YamazakiM., TojoA., and KagamiH.Feasibility and efficacy of bone tissue engineering using human bone marrow stromal cells cultivated in serum-free conditions. Biochem Biophys Res Commun, 382, 353, 2009.
47.
SatoK., ItohT., KatoT., KitamuraY., KaulS.C., WadhwaR., SatoF., and OhnedaO.Serum-free isolation and culture system to enhance the proliferation and bone regeneration of adipose tissue-derived mesenchymal stem cells. In Vitro Cell Dev Biol Anim, 51, 515, 2015.
48.
CousinM.A., GreenbergA.J., KoepT.H., AngiusD., YaszemskiM.J., SpinnerR.J., and WindebankA.J.The value of systematic reviews in estimating the cost and barriers to translation in tissue engineering. Tissue Eng Part B Rev, 22, 430, 2016.
49.
ChimentiI., GaetaniR., ForteE., AngeliniF., De FalcoE., ZoccaiG.B., MessinaE., FratiG., and GiacomelloA.Serum and supplement optimization for EU GMP-compliance in cardiospheres cell culture. J Cell Mol Med, 18, 624, 2014.
50.
KuritaM., Aiba-KojimaE., ShigeuraT., MatsumotoD., SugaH., InoueK., EtoH., KatoH., AoiN., and YoshimuraK.Differential effects of three preparations of human serum on expansion of various types of human cells. Plast Reconstr Surg, 122, 438, 2008.
51.
MuragliaA., TodeschiM.R., PapaitA., PoggiA., SpanoR., StradaP., CanceddaR., and MastrogiacomoM.Combined platelet and plasma derivatives enhance proliferation of stem/progenitor cells maintaining their differentiation potential. Cytotherapy, 17, 1793, 2015.
52.
ZimmermannR., ArnoldD., StrasserE., RingwaldJ., SchlegelA., WiltfangJ., and EcksteinR.Sample preparation technique and white cell content influence the detectable levels of growth factors in platelet concentrates. Vox Sang, 85, 283, 2003.
53.
WeibrichG., HansenT., KleisW., BuchR., and HitzlerW.E.Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. Bone, 34, 665, 2004.
54.
KawasumiM., KitohH., SiwickaK.A., and IshiguroN.The effect of the platelet concentration in platelet-rich plasma gel on the regeneration of bone. J Bone Joint Surg Br, 90, 966, 2008.
55.
StuteN., HoltzK., BubenheimM., LangeC., BlakeF., and ZanderA.R.Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use. Exp Hematol, 32, 1212, 2004.
56.
ShahdadfarA., FronsdalK., HaugT., ReinholtF.P., and BrinchmannJ.E.In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells, 23, 1357, 2005.
57.
Perez-IlzarbeM., Diez-CampeloM., ArandaP., TaberaS., LopezT., del CanizoC., MerinoJ., MorenoC., AndreuE.J., ProsperF., and Perez-SimonJ.A.Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion (Paris), 49, 1901, 2009.
58.
BiebackK., HeckerA., KocaomerA., LannertH., SchallmoserK., StrunkD., and KluterH.Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells, 27, 2331, 2009.
59.
FeketeN., RojewskiM.T., LotfiR., and SchrezenmeierH.Essential components for ex vivo proliferation of mesenchymal stromal cells. Tissue Eng Part C Methods, 20, 129, 2014.
60.
WuchterP., VetterM., SaffrichR., DiehlmannA., BiebackK., HoA.D., and HornP.Evaluation of GMP-compliant culture media for in vitro expansion of human bone marrow mesenchymal stromal cells. Exp Hematol, 44, 508, 2016.
61.
HornP., BokermannG., CholewaD., BorkS., WalendaT., KochC., DrescherW., HutschenreutherG., ZenkeM., HoA.D., and WagnerW.Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells. Cytotherapy, 12, 888, 2010.
62.
WeibrichG., KleisW.K., HafnerG., and HitzlerW.E.Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg, 30, 97, 2002.
63.
WeibrichG., BuchR.S., KleisW.K., HafnerG., HitzlerW.E., and WagnerW.Quantification of thrombocyte growth factors in platelet concentrates produced by discontinuous cell separation. Growth Factors, 20, 93, 2002.
64.
ChoH.S., SongI.H., ParkS.Y., SungM.C., AhnM.W., and SongK.E.Individual variation in growth factor concentrations in platelet-rich plasma and its influence on human mesenchymal stem cells. Korean J Lab Med, 31, 212, 2011.
65.
LohmannM., WalendaG., HemedaH., JoussenS., DrescherW., JockenhoevelS., HutschenreuterG., ZenkeM., and WagnerW.Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells. PLoS One, 7, e37839, 2012.
66.
EvansonJ.R., GuytonM.K., OliverD.L., HireJ.M., TopolskiR.L., ZumbrunS.D., McPhersonJ.C., and BojesculJ.A.Gender and age differences in growth factor concentrations from platelet-rich plasma in adults. Mil Med, 179, 799, 2014.
67.
GomezL.A., EscobarM., and PenuelaO.Standardization of a protocol for obtaining platelet rich plasma from blood donors; a tool for tissue regeneration procedures. Clin Lab, 61, 973, 2015.
68.
MarxR.E.Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg, 62, 489, 2004.
69.
European Directorate for the Quality of Medicines & Healthcare. Guide to the Preparation, Use and Quality Assurance of Blood Components. Strasbourg, France: Council of Europe. Recommendation No. R (95), 15, 2015.
70.
Jonsdottir-BuchS.M., LiederR., and SigurjonssonO.E.Platelet lysates produced from expired platelet concentrates support growth and osteogenic differentiation of mesenchymal stem cells. PLoS One, 8, e68984, 2013.
71.
ZimmermannR., JakubietzR., JakubietzM., StrasserE., SchlegelA., WiltfangJ., and EcksteinR.Different preparation methods to obtain platelet components as a source of growth factors for local application. Transfusion (Paris), 41, 1217, 2001.
72.
WasterlainA.S., BraunH.J., and DragooJ.L.Contents and formulations of platelet-rich plasma. Oper Tech Orthop, 22, 33, 2012.
73.
SchallmoserK., and StrunkD.Generation of a pool of human platelet lysate and efficient use in cell culture. Methods Mol Biol, 946, 349, 2013.
74.
KocaoemerA., KernS., KluterH., and BiebackK.Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells, 25, 1270, 2007.
75.
MarxR.E.Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent, 10, 225, 2001.
76.
JalowiecJ.M., D'EsteM., BaraJ.J., DenomJ., MenzelU., AliniM., VerrierS., and HerrmannM.An in vitro investigation of platelet-rich plasma-gel as a cell and growth factor delivery vehicle for tissue engineering. Tissue Eng Part C Methods, 22, 49, 2016.
77.
FosterT.E., PuskasB.L., MandelbaumB.R., GerhardtM.B., and RodeoS.A.Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med, 37, 2259, 2009.
78.
RohY.H., KimW., ParkK.U., and OhJ.H.Cytokine-release kinetics of platelet-rich plasma according to various activation protocols. Bone Joint Res, 5, 37, 2016.
79.
AmableP.R., CariasR.B., TeixeiraM.V., da Cruz PachecoI., Correa do AmaralR.J., GranjeiroJ.M., and BorojevicR.Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther, 4, 67, 2013.
80.
FeketeN., GadelorgeM., FurstD., MaurerC., DausendJ., Fleury-CappellessoS., MailanderV., LotfiR., IgnatiusA., SensebeL., BourinP., SchrezenmeierH., and RojewskiM.T.Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy, 14, 540, 2012.
81.
ShanskiiY.D., SergeevaN.S., SviridovaI.K., KirakozovM.S., KirsanovaV.A., AkhmedovaS.A., AntokhinA.I., and ChissovV.I.Human platelet lysate as a promising growth-stimulating additive for culturing of stem cells and other cell types. Bull Exp Biol Med, 156, 146, 2013.
82.
AatonenM.T., OhmanT., NymanT.A., LaitinenS., GronholmM., and SiljanderP.R.Isolation and characterization of platelet-derived extracellular vesicles. J Extracell Vesicles, 3, 2014. doi: 10.3402/jev.v3.24692.
83.
TorreggianiE., PerutF., RoncuzziL., ZiniN., BaglioS.R., and BaldiniN.Exosomes: novel effectors of human platelet lysate activity. Eur Cell Mater, 28, 137, 2014.
84.
GruberR., VargaF., FischerM.B., and WatzekG.Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. Clin Oral Implants Res, 13, 529, 2002.
85.
RodriguesM., GriffithL.G., and WellsA.Growth factor regulation of proliferation and survival of multipotential stromal cells. Stem Cell Res Ther, 1, 32, 2010.
86.
HughesF.J., TurnerW., BelibasakisG., and MartuscelliG.Effects of growth factors and cytokines on osteoblast differentiation. Periodontol 2000, 41, 48, 2006.
87.
DonovanJ., AbrahamD., and NormanJ.Platelet-derived growth factor signaling in mesenchymal cells. Front Biosci (Landmark Ed), 18, 106, 2013.
88.
NgF., BoucherS., KohS., SastryK.S., ChaseL., LakshmipathyU., ChoongC., YangZ., VemuriM.C., RaoM.S., and TanavdeV.PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood, 112, 295, 2008.
89.
EomY.W., OhJ.E., LeeJ.I., BaikS.K., RheeK.J., ShinH.C., KimY.M., AhnC.M., KongJ.H., KimH.S., and ShimK.Y.The role of growth factors in maintenance of stemness in bone marrow-derived mesenchymal stem cells. Biochem Biophys Res Commun, 445, 16, 2014.
90.
CraneJ.L., and CaoX.Bone marrow mesenchymal stem cells and TGF-beta signaling in bone remodeling. J Clin Invest, 124, 466, 2014.
91.
LeototJ., CoquelinL., BodivitG., BierlingP., HernigouP., RouardH., and ChevallierN.Platelet lysate coating on scaffolds directly and indirectly enhances cell migration, improving bone and blood vessel formation. Acta Biomater, 9, 6630, 2013.
92.
UristM.R.Bone morphogenetic protein: the molecularization of skeletal system development. J Bone Miner Res, 12, 343, 1997.
93.
ChengH., JiangW., PhillipsF.M., HaydonR.C., PengY., ZhouL., LuuH.H., AnN., BreyerB., VanichakarnP., SzatkowskiJ.P., ParkJ.Y., and HeT.C.Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am, 85-A, 1544, 2003.
94.
LuuH.H., SongW.X., LuoX., ManningD., LuoJ., DengZ.L., SharffK.A., MontagA.G., HaydonR.C., and HeT.C.Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res, 25, 665, 2007.
95.
SipeJ.B., ZhangJ., WaitsC., SkikneB., GarimellaR., and AndersonH.C.Localization of bone morphogenetic proteins (BMPs)-2, -4, and -6 within megakaryocytes and platelets. Bone, 35, 1316, 2004.
96.
KalenA., WahlstromO., LinderC.H., and MagnussonP.The content of bone morphogenetic proteins in platelets varies greatly between different platelet donors. Biochem Biophys Res Commun, 375, 261, 2008.
97.
TomoyasuA., HigashioK., KanomataK., GotoM., KodairaK., SerizawaH., SudaT., NakamuraA., NojimaJ., FukudaT., and KatagiriT.Platelet-rich plasma stimulates osteoblastic differentiation in the presence of BMPs. Biochem Biophys Res Commun, 361, 62, 2007.
98.
BaikS.Y., LimY.A., KangS.J., AhnS.H., LeeW.G., and KimC.H.Effects of platelet lysate preparations on the proliferation of HaCaT cells. Ann Lab Med, 34, 43, 2014.
99.
NugrahaY., SariP., PurwokoR.Y., LuviahE., and PawitanJ.A.Effect of lysed platelet count in platelet concentrates on various growth factor levels after freeze rhaw cycles. Int J PharmTech Res, 6, 2036, 2014.
100.
StrandbergG., SellbergF., SommarP., RonaghiM., LubenowN., KnutsonF.and Berglund, D. Standardizing the freeze-thaw preparation of growth factors from platelet lysate. Transfusion, 57, 1058, 2017.
101.
Mojica-HenshawM.P., JacobsonP., MorrisJ., KelleyL., PierceJ., BoyerM., and ReemsJ.A.Serum-converted platelet lysate can substitute for fetal bovine serum in human mesenchymal stromal cell cultures. Cytotherapy, 15, 1458, 2013.
102.
DeshpandeS., JamesA.W., BloughJ., DonneysA., WangS.C., CedernaP.S., BuchmanS.R., and LeviB.Reconciling the effects of inflammatory cytokines on mesenchymal cell osteogenic differentiation. J Surg Res, 185, 278, 2013.
103.
LiC., LiG., LiuM., ZhouT., and ZhouH.Paracrine effect of inflammatory cytokine-activated bone marrow mesenchymal stem cells and its role in osteoblast function. J Biosci Bioeng, 121, 213, 2016.
104.
PourgholaminejadA., AghdamiN., BaharvandH., and MoazzeniS.M.The effect of pro-inflammatory cytokines on immunophenotype, differentiation capacity and immunomodulatory functions of human mesenchymal stem cells. Cytokine, 85, 51, 2016.
105.
CroesM., OnerF.C., KruytM.C., BlokhuisT.J., BastianO., DhertW.J., and AlblasJ.Proinflammatory mediators enhance the osteogenesis of human mesenchymal stem cells after lineage commitment. PLoS One, 10, e0132781, 2015.
106.
MountziarisP.M., and MikosA.G.Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng Part B Rev, 14, 179, 2008.
107.
KinzebachS., DietzL., KluterH., ThierseH.J., and BiebackK.Functional and differential proteomic analyses to identify platelet derived factors affecting ex vivo expansion of mesenchymal stromal cells. BMC Cell Biol, 14, 48, 2013.
108.
RennT.Y., KaoY.H., WangC.C., and BurnoufT.Anti-inflammatory effects of platelet biomaterials in a macrophage cellular model. Vox Sang, 109, 138, 2015.
109.
FrechetteJ.P., MartineauI., and GagnonG.Platelet-rich plasmas: growth factor content and roles in wound healing. J Dent Res, 84, 434, 2005.
110.
HartwigD., HartelC., HennigH., Muller-SteinhardtM., SchlenkeP., and KluterH.Evidence for de novo synthesis of cytokines and chemokines in platelet concentrates. Vox Sang, 82, 182, 2002.
111.
KarpJ.M., SarrafF., ShoichetM.S., and DaviesJ.E.Fibrin-filled scaffolds for bone-tissue engineering: an in vivo study. J Biomed Mater Res A, 71, 162, 2004.
112.
NikolidakisD., van den DolderJ., WolkeJ.G., StoelingaP.J., and JansenJ.A.The effect of platelet-rich plasma on the bone healing around calcium phosphate-coated and non-coated oral implants in trabecular bone. Tissue Eng, 12, 2555, 2006.
113.
RoussyY., Bertrand DuchesneM.P., and GagnonG.Activation of human platelet-rich plasmas: effect on growth factors release, cell division and in vivo bone formation. Clin Oral Implants Res, 18, 639, 2007.
114.
HanB., Woodell-MayJ., PonticielloM., YangZ., and NimniM.The effect of thrombin activation of platelet-rich plasma on demineralized bone matrix osteoinductivity. J Bone Joint Surg Am, 91, 1459, 2009.
115.
Ben AzounaN., JenhaniF., RegayaZ., BerraeisL., Ben OthmanT., DucrocqE., and DomenechJ.Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res Ther, 3, 6, 2012.
116.
LawsonJ.H.The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost, 32Suppl 1, 98, 2006.
117.
AltaieA., OwstonH., and JonesE.Use of platelet lysate for bone regeneration—are we ready for clinical translation? World J Stem Cells, 8, 47, 2016.
118.
MohammadiS., NikbakhtM., Malek MohammadiA., Zahed PanahM., OstadaliM.R., NasiriH., and GhavamzadehA.Human platelet lysate as a xeno free alternative of fetal bovine serum for the in vitro expansion of human mesenchymal stromal cells. Int J Hematol Oncol Stem Cell Res, 10, 161, 2016.
119.
FazzinaR., IudiconeP., FioravantiD., BonannoG., TottaP., ZizzariI.G., and PierelliL.Potency testing of mesenchymal stromal cell growth expanded in human platelet lysate from different human tissues. Stem Cell Res Ther, 7, 122, 2016.
120.
LiC.Y., WuX.Y., TongJ.B., YangX.X., ZhaoJ.L., ZhengQ.F., ZhaoG.B., and MaZ.J.Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy. Stem Cell Res Ther, 6, 55, 2015.
121.
BrennanM.A., RenaudA., AmiaudJ., RojewskiM.T., SchrezenmeierH., HeymannD., TrichetV., and LayrolleP.Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate. Stem Cell Res Ther, 5, 114, 2014.
122.
University of Bergen, Jaw Bone Reconstruction Using a Combination of Autologous Mesenchymal Stem Cells and Biomaterial Prior to Dental Implant Placement. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US) 2000–2016. Available at: https://clinicaltrialsgov/ct2/show/NCT027511252016 Accessed January20, 2017.
123.
AminiA.R., LaurencinC.T., and NukavarapuS.P.Bone tissue engineering: recent advances and challenges. Crit Rev Biomed Eng, 40, 363, 2012.
124.
NguyenL.H., AnnabiN., NikkhahM., BaeH., BinanL., ParkS., KangY., YangY., and KhademhosseiniA.Vascularized bone tissue engineering: approaches for potential improvement. Tissue Eng Part B Rev, 18, 363, 2012.
125.
MartinezC.E., SmithP.C., and Palma AlvaradoV.A.The influence of platelet-derived products on angiogenesis and tissue repair: a concise update. Front Physiol, 6, 290, 2015.
126.
BarsottiM.C., LosiP., BrigantiE., SanguinettiE., MageraA., Al KayalT., FerianiR., Di StefanoR., and SoldaniG.Effect of platelet lysate on human cells involved in different phases of wound healing. PLoS One, 8, e84753, 2013.
127.
EtulainJ., FondevilaC., NegrottoS., and SchattnerM.Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin. Br J Pharmacol, 170, 255, 2013.
128.
HoferH.R., and TuanR.S.Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies. Stem Cell Res Ther, 9, 131, 2016.
129.
MadrigalM., RaoK.S., and RiordanN.H.A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J Transl Med, 11, 260, 2014.
130.
AbdelrazikH., SpaggiariG.M., ChiossoneL., and MorettaL.Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur J Immunol, 41, 3281, 2011.
131.
UliviV., TassoR., CanceddaR., and DescalziF.Mesenchymal stem cell paracrine activity is modulated by platelet lysate: induction of an inflammatory response and secretion of factors maintaining macrophages in a proinflammatory phenotype. Stem Cells Dev, 15, 1858, 2014.
132.
WagnerW., HoA.D., and ZenkeM.Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Rev, 16, 445, 2010.
133.
TurinettoV., VitaleE., and GiachinoC.Senescence in human mesenchymal stem cells: functional changes and implications in stem cell-based therapy. Int J Mol Sci, 17, pii:E1164, 2016.
134.
CholewaD., StiehlT., SchellenbergA., BokermannG., JoussenS., KochC., WalendaT., PalluaN., Marciniak-CzochraA., SuschekC.V., and WagnerW.Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transplant, 20, 1409, 2011.
135.
BiebackK., HeckerA., SchlechterT., HofmannI., BrousosN., RedmerT., BesserD., KlüterH., MüllerA.M., and BeckerM.Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum. Cytotherapy, 14, 570, 2012.
136.
SchallmoserK., BartmannC., RohdeE., BorkS., GuellyC., ObenaufA.C., ReinischA., HornP., HoA.D., StrunkD., and WagnerW.Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica, 95, 867, 2010.
137.
GriffithsS., BaraniakP.R., CoplandI.B., NeremR.M., and McDevittT.C.Human platelet lysate stimulates high-passage and senescent human multipotent mesenchymal stromal cell growth and rejuvenation in vitro. Cytotherapy, 12, 1469, 2013.
138.
PlachokovaA.S., NikolidakisD., MulderJ., JansenJ.A., and CreugersN.H.Effect of platelet-rich plasma on bone regeneration in dentistry: a systematic review. Clin Oral Implants Res, 19, 539, 2008.
139.
YamadaY., NakamuraS., ItoK., UmemuraE., HaraK., NagasakaT., AbeA., BabaS., FuruichiY., IzumiY., KleinO.D., and WakabayashiT.Injectable bone tissue engineering using expanded mesenchymal stem cells. Stem cells (Dayton, Ohio), 31, 572, 2013.
140.
PocaterraA., CarusoS., BernardiS., ScagnoliL., ContinenzaM.A., and GattoR.Effectiveness of platelet-rich plasma as an adjunctive material to bone graft: a systematic review and meta-analysis of randomized controlled clinical trials. Int J Oral Maxillofac Surg, 45, 1027, 2016.
141.
CentenoC.J., SchultzJ.R., CheeverM., FreemanM., FaulknerS., RobinsonB., and HansonR.Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther, 6, 368, 2011.
142.
ZhangJ., HuangX., WangH., LiuX., ZhangT., WangY., and HuD.The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res Ther, 6, 234, 2015.
143.
OtsuruS., GordonP.L., ShimonoK., JethvaR., MarinoR., PhillipsC.L., HofmannT.J., VeronesiE., DominiciM., IwamotoM., and HorwitzE.M.Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood, 120, 1933, 2012.
144.
GuptaP.K., ChullikanaA., RengasamyM., ShettyN., PandeyV., AgarwalV., WaghS.Y., VellotareP.K., DamodaranD., ViswanathanP., ThejC., BalasubramanianS., and MajumdarA.S.Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®): preclinical and clinical trial in osteoarthritis of the knee joint. Arthritis Res Ther, 18, 301, 2016.
145.
von BoninM., StölzelF., GoedeckeA., RichterK., WuschekN., HöligK., PlatzbeckerU., IllmerT., SchaichM., ScheteligJ., KianiA., OrdemannR., EhningerG., SchmitzM., and BornhäuserM.Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant, 43, 245, 2009.
146.
LucchiniG., IntronaM., DanderE., RovelliA., BalduzziA., BonanomiS., SalvadèA., CapelliC., BelottiD., GaipaG., PerseghinP., VinciP., LaninoE., ChiusoloP., OrofinoM.G., MarktelS., GolayJ., RambaldiA., BiondiA., D'AmicoG., and BiagiE.Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant, 16, 1293, 2010.
147.
KuçiZ., BönigH., KreyenbergH., BunosM., JauchA., JanssenJ.W., ŠkifićM., MichelK., EisingB., LucchiniG., BakhtiarS., GreilJ., LangP., BasuO., von LuettichauI., SchulzA., SykoraK.W., JarischA., SoerensenJ., Salzmann-ManriqueE., SeifriedE., KlingebielT., BaderP., and KuçiS.Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica, 101, 985, 2016.
148.
SakamotoN., TsujiK., MuulL.M., LawlerA.M., PetricoinE.F., CandottiF., MetcalfJ.A., TavelJ.A., LaneH.C., UrbaW.J., FoxB.A., VarkiA., LunneyJ.K., and RosenbergA.S.Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood, 110, 501, 2007.
149.
HaqueN., Abu KasimN.H., and RahmanM.T.Optimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cells. Int J Biol Sci, 11, 324, 2015.
150.
SiddappaR., LichtR., van BlitterswijkC., and de BoerJ.Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J Orthop Res, 25, 1029, 2007.
151.
FazzinaR., IudiconeP., FioravantiD., BonannoG., TottaP., ZizzariI.G., and PierelliL.Potency testing of mesenchymal stromal cell growth expanded in human platelet lysate from different human tissues. Stem Cell Res Ther, 6, 55, 2015.
152.
DeeksJ.J., HigginsJ.P.T., and AltmanD.G.Analysing data and undertaking meta-analyses. In: HigginsJ.P., and GreenS., eds. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Chichester, United Kingdom: John Wiley & Sons, Ltd, 2008, pp. 243.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
